All Stories

  1. In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases

    Article • Antimicrobial Agents and Chemotherapy, January 2015, ASM Journals

    Dr Ken Coleman

  2. Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases

    Article • Antimicrobial Agents and Chemotherapy, August 2014, ASM Journals

    Dr Prema Levasseur, Dr Ken Coleman

  3. Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

    Article • Antimicrobial Agents and Chemotherapy, March 2014, ASM Journals

    Dr Ken Coleman

  4. Activated ClpP kills persisters and eradicates a chronic biofilm infection

    Article • Nature, November 2013, Springer Science + Business Media

    Dr Ken Coleman

  5. In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

    Article • Antimicrobial Agents and Chemotherapy, January 2012, ASM Journals

    Dr Christine Miossec, Dr Ken Coleman

  6. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

    Article • Current Opinion in Microbiology, October 2011, Elsevier

    Dr Ken Coleman

  7. Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor

    Article • Antimicrobial Agents and Chemotherapy, October 2010, ASM Journals

    Dr Christine Miossec, Dr Ken Coleman

  8. Extending the life of β-lactam antibiotics: New β-lactamase inhibitors

    Article • Drug Discovery Today Therapeutic Strategies, June 2006, Elsevier

    Dr Ken Coleman

  9. Recent advances in the treatment of Gram-positive infections

    Article • Drug Discovery Today Therapeutic Strategies, December 2004, Elsevier

    Dr Ken Coleman

  10. Effect of extended pre-incubation with chlamydia pneumoniae and extended incubation with antimicrobial on the minimum inhibitory concentrations (MICs) of five antimicrobials

    Article • Diagnostic Microbiology and Infectious Disease, August 2001, Elsevier

    Dr Ken Coleman

  11. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro

    Article • Journal of Antimicrobial Chemotherapy, April 2000, Oxford University Press (OUP)

    Dr Paul G Higgins, Dr Ken Coleman

  12. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

    Article • Journal of Antimicrobial Chemotherapy, April 2000, Oxford University Press (OUP)

    Dr Ken Coleman

  13. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA

    Article • Journal of Antimicrobial Chemotherapy, April 2000, Oxford University Press (OUP)

    Dr Ken Coleman

  14. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae

    Article • Journal of Antimicrobial Chemotherapy, April 2000, Oxford University Press (OUP)

    Dr Ken Coleman

  15. Rapid detection of antimicrobial activity using flow cytometry

    Article • Cytometry, December 1995, Wiley

    Dr Ken Coleman

  16. Section Review: Anti-infectives: An update on β-lactamases and β-lactamase inhibitors

    Article • Expert Opinion on Investigational Drugs, August 1995, Informa Healthcare

    Dr Ken Coleman

  17. The application of flow cytometry to the estimation of bacterial antibiotic susceptibility

    Article • Journal of Antimicrobial Chemotherapy, January 1995, Oxford University Press (OUP)

    Dr Ken Coleman

  18. Bacterial resistance mechanisms as therapeutic targets

    Article • Journal of Antimicrobial Chemotherapy, January 1994, Oxford University Press (OUP)

    Dr Ken Coleman

  19. Characterization of Bacterial Cell Size and Ploidy using Flow Cytometry and Image Analysis

    Article • January 1993, Springer Science + Business Media

    Dr Ken Coleman

  20. Pharmacokinetic studies and renal dehydropeptidase stability of the new beta-lactamase inhibitor BRL 42715 in animals.

    Article • Antimicrobial Agents and Chemotherapy, September 1991, ASM Journals

    Dr Ken Coleman

  21. The automated in-vitro assesment of β-lactamase inhibitors

    Article • Journal of Antimicrobial Chemotherapy, January 1991, Oxford University Press (OUP)

    Dr Ken Coleman

  22. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. V. Chiral 1,2,3-triazolyl derivatives.

    Article • The Journal of Antibiotics, January 1991, Japan Antibiotics Research Association

    Dr Ken Coleman

  23. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. III. Structure-activity relationships of the 5-membered heterocyclic derivatives.

    Article • The Journal of Antibiotics, January 1991, Japan Antibiotics Research Association

    Dr Ken Coleman

  24. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. IV. Kidney stability, serum binding and additional biological evaluation of racemic derivatives.

    Article • The Journal of Antibiotics, January 1991, Japan Antibiotics Research Association

    Dr Ken Coleman

  25. 6-(Substituted methylene)penems, potent broad spectrum inhibitors of bacterial .BETA.-lactamase. II. Racemic furyl and thienyl derivatives.

    Article • The Journal of Antibiotics, January 1990, Japan Antibiotics Research Association

    Dr Ken Coleman

  26. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.

    Article • Antimicrobial Agents and Chemotherapy, September 1989, ASM Journals

    Dr Ken Coleman

  27. Synthesis and .BETA.-lactamase inhibitory activity of 9-(2-amidoethenylthio)-9-deoxy derivatives of clavulanic acid.

    Article • The Journal of Antibiotics, January 1988, Japan Antibiotics Research Association

    Dr Ken Coleman

  28. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin

    Article • Journal of Antimicrobial Chemotherapy, January 1980, Oxford University Press (OUP)

    Dr Ken Coleman

  29. Antimicrobial substances and chick growth promotion: Comparative studies on selected compoundsin vitroandin vivo

    Article • British Poultry Science, May 1977, Taylor & Francis

    Dr Ken Coleman

  30. Antimicrobial substances and chick growth promotion: The growth‐promoting activities of antimicrobial substances, including fifty‐two used either in therapy or as dietary additives

    Article • British Poultry Science, May 1977, Taylor & Francis

    Dr Ken Coleman